BioLineRx Ltd. Sponsored American Depositary Receipt (BLRX)

Overview

BioLineRx Ltd. is a pre-commercial-stage biopharmaceutical company with a strong focus on oncology. Established in 2003 and headquartered in Modi'in, Israel, the company is engaged in the development of innovative therapies aimed at addressing unmet medical needs in the treatment of cancer and other serious diseases. Through its robust pipeline of pharmaceutical products in various stages of clinical development, BioLineRx demonstrates a commitment to science-driven solutions that can potentially improve patient outcomes in areas of high medical demand. The company has established collaboration agreements with notable entities such as MSD and MD Anderson Cancer Center, indicating its strategic approach to development and the significance of its product portfolio in the cancer immunotherapy field. Additionally, BioLineRx has a licensing arrangement with Perrigo Company plc, expanding its reach into over-the-counter pharmaceuticals.

Products and Services

• Motixafortide

This leading compound is a peptide currently under development for multiple therapeutic uses. It has completed Phase 3 clinical trials for autologous stem cell mobilization, showing its potential in enhancing the collection of a patient's own stem cells for transplantation purposes. Furthermore, Motixafortide has been tested in Phase 2a clinical trials for the treatment of pancreatic cancer, demonstrating BioLineRx's commitment to combating this challenging disease. The drug is also in Phase 2 clinical trials targeting metastatic pancreatic adenocarcinoma and Phase 1b trials for treating acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections. Additionally, its application extends to the treatment of solid tumors and acute myeloid leukemia, showcasing its versatility as a therapeutic agent.

• AGI-134

An innovative immuno-oncology agent, AGI-134 is currently in Phase 1/2a clinical trials for the treatment of solid tumors. By stimulating the body's immune system to attack cancer cells, this product represents BioLineRx's investment in next-generation cancer therapies that seek to harness the power of the immune system in the fight against cancer.

• BL-5010

This product is a proprietary, pen-like applicator designed for the non-surgical removal of skin lesions. BioLineRx has entered into a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010, making it an accessible solution for individuals seeking a non-invasive option for the treatment of skin lesions. This diversification into skincare products highlights the company's broader vision toward addressing various patient needs through innovative technologies.